GLP-1 plateaus: what the dose-escalation science actually shows

What did @therealdrleemd actually say?

The creator, identifying as "TikTok's favorite doc," laid out a three-step protocol for GLP-1 users who've stopped losing weight. The core advice: a "true plateau" means eight to twelve weeks with no weight loss, and the fix is stepping up one dose level. Specifically, they said moving from "five milligrams" to "7.5 milligrams" is the right move, with reassessment at eight weeks. They also warned against chasing the top dose, suggesting "12.5 to 15 milligrams is usually for early plateau or weight gain" and that side effects, not efficacy, often determine your effective ceiling. The video ends with a soft pitch to DM or use their platform for care.

To be clear: this reads as tirzepatide dosing advice, though the creator never names the drug. The five, 7.5, 10, 12.5, and 15 mg increments match Mounjaro and Zepbound's approved titration schedule exactly.

Does the science back this up?

Partially. The plateau definition and the dose-step logic have real clinical grounding, but the framing oversimplifies what the research actually shows about who benefits from escalation versus who doesn't.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 10 and 15 mg produced significantly greater weight loss than lower doses, but individual response varied considerably. Roughly 20-30% of participants in lower-dose arms achieved clinically meaningful weight loss without needing maximum doses. That supports the creator's point about not chasing the ceiling, but it also means dose escalation isn't the universal answer the video implies.

On the plateau definition itself, eight to twelve weeks without movement is a reasonable clinical threshold. A 2023 analysis by Aronne et al. in Obesity found that weight loss trajectories on semaglutide often slow between months three and six before stabilizing, which means some apparent plateaus are just normal deceleration, not true treatment failure. The creator doesn't distinguish between those two scenarios, which is a meaningful gap.

What did they get wrong (or right)?

Credit where it's due: the advice to reassess in eight weeks rather than immediately escalating, and to watch "weight trends, appetite, and tolerability" together, is actually reasonable. Too many social media voices push for faster escalation than guidelines support.

However, the statement that "12.5 to 15 milligrams is usually for early plateau or weight gain" is confusing and potentially backwards. Higher doses are typically reserved for patients who haven't reached their weight loss goal at lower doses and who are tolerating the medication well, not specifically for "early" plateau. The American Diabetes Association's 2024 Standards of Care are explicit that escalation decisions should be individualized based on both efficacy and tolerability, not mapped to plateau timing the way the creator describes.

The video also skips entirely over non-pharmacological reasons for a plateau: dietary drift, reduced activity adaptation, changes in sleep or stress, or medication adherence issues. Jumping straight to dose adjustment without ruling those out is a clinical shortcut that isn't supported by the evidence base.

What should you actually know?

A plateau on a GLP-1 medication does not automatically mean you need a higher dose. That's the key fact missing from this video.

A 2023 real-world cohort study by Wharton et al. in Diabetes, Obesity and Metabolism found that a significant subset of patients on semaglutide maintained weight loss at stable doses for twelve-plus months without further escalation. Individual ceiling doses exist, and they're not the same for everyone. Side effect burden, which the creator briefly acknowledges, is a legitimate clinical signal that your body may not tolerate a higher dose, even if you haven't hit your goal weight.

Dose changes on GLP-1 medications should happen through a licensed provider who has access to your full history, lab values, and any comorbidities. A TikTok comment thread or a DM is not that. If you're on a GLP-1 and feel stuck, that conversation belongs with your prescriber, not a social media algorithm.